Skip to main content

Table 3 Number of patients with decreased or increased levels of RANKL, IL-6, TNF-RI, ACPA and ACPA fine specificities at follow-up

From: Serum RANKL levels associate with anti- citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexate

 

Number of patients with decreased levels

Number of patients with unchanged or increased levels

Total number of patients

RANKL

145 (83 %)

29 (17 %)

174

IL-6

120 (68 %)

56 (32 %)

176

TNF-RI

124 (70 %)

52 (30 %)

176

ACPA

107 (89 %)

13 (11 %)

120

Anti-cit-enolase (amino acids 5–21)

58 (82 %)

13 (18 %)

71

Anti-cit-vimentin (amino acids 60–75)

59 (88 %)

8 (12 %)

67

Anti-cit-fibrinogen (amino acids 563–583)

35 (83 %)

7 (17 %)

42

  1. Values are given as number (%). We report change in antibody concentrations for patients being positive at baseline or at 3 month for the corresponding antibody
  2. RANKL receptor activator of nuclear factor kappa B ligand, IL interleukin, TNF-RI tumor necrosis factor receptor type I, ACPA anti-citrullinated protein antibodies, cit citrullinated